Aven overexpression: Association with poor prognosis in childhood acute lymphoblastic leukemia

被引:21
作者
Choi, Jaewon
Hwang, Yu Kyeong
Sung, Ki Woong
Kim, Dong Hyun
Yoo, Keon Hee
Jung, Hye Lim
Koo, Hong Hoe
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Biomed Res Inst,Dept Pediat, Seoul 135710, South Korea
[2] Mogam Biotechnol Res Inst, Div Immunotherapy, Yongin, South Korea
关键词
Aven; apoptosis; acute lymphoblastic leukemia; prognostic factors; quantitative RT-PCR; children;
D O I
10.1016/j.leukres.2005.11.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aven expression has recently been identified as an anti-apoptotic protein. In this study, Aven expression in 91 children with acute lymphoblastic leukemia (ALL) was investigated for possible correlation with clinical features at diagnosis and treatment outcome. Aven expression was found to be higher in patients >= 10 years old or < 1 year (P=0.003), and in patients with unfavorable cytogenetic abnormalities (P < 0.001). Aven expression was also significantly higher in relapsed patients in the standard-risk group. Aven overexpression was an independent poor Prognostic factor. These findings demonstrate that Aven expression can predict prognosis in childhood ALL. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1019 / 1025
页数:7
相关论文
共 39 条
[1]   Outcome of treatment in children with philadelphia chromosome-positive acute lymphoblastic leukemia [J].
Aricò, M ;
Valsecchi, MG ;
Camitta, B ;
Schrappe, M ;
Chessells, J ;
Baruchel, A ;
Gaynon, P ;
Silverman, L ;
Janka-Schaub, G ;
Kamps, W ;
Pui, CH ;
Masera, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (14) :998-1006
[2]   Portal hypertension develops in a subset of children with standard risk acute lymphoblastic leukemia treated with oral 6-thioguanine during maintenance therapy [J].
Broxson, EH ;
Dole, M ;
Wong, R ;
Laya, BF ;
Stork, L .
PEDIATRIC BLOOD & CANCER, 2005, 44 (03) :226-231
[3]   Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1 [J].
Chau, BN ;
Cheng, EHY ;
Kerr, DA ;
Hardwick, JM .
MOLECULAR CELL, 2000, 6 (01) :31-40
[4]  
CHEN CS, 1993, BLOOD, V81, P2386
[5]   c-IAP1 is cleaved by caspases to produce a proapoptotic C-terminal fragment [J].
Clem, RJ ;
Sheu, TT ;
Richter, BWM ;
He, WW ;
Thornberry, NA ;
Duckett, CS ;
Hardwick, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (10) :7602-7608
[6]   Endogenous inhibitors of caspases [J].
Deveraux, QL ;
Stennicke, HR ;
Salvesen, GS ;
Reed, JC .
JOURNAL OF CLINICAL IMMUNOLOGY, 1999, 19 (06) :388-398
[7]   Genomic approaches to hematologic malignancies [J].
Ebert, BL ;
Golub, TR .
BLOOD, 2004, 104 (04) :923-932
[8]   Control of apoptosis by p53 [J].
Fridman, JS ;
Lowe, SW .
ONCOGENE, 2003, 22 (56) :9030-9040
[9]   IMPROVED THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA AND UNFAVORABLE PRESENTING FEATURES - A FOLLOW-UP REPORT OF THE CHILDRENS CANCER GROUP-STUDY CCG-106 [J].
GAYNON, PS ;
STEINHERZ, PG ;
BLEYER, WA ;
ABLIN, AR ;
ALBO, VC ;
FINKLESTEIN, JZ ;
GROSSMAN, NJ ;
NOVAK, LJ ;
PYESMANY, AF ;
REAMAN, GH ;
CHAPPELL, RJ ;
SATHER, HN ;
HAMMOND, GD .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (11) :2234-2242
[10]   Genomic approaches to the pathogenesis of hematologic malignancy [J].
Golub, TR .
CURRENT OPINION IN HEMATOLOGY, 2001, 8 (04) :252-261